Alkermes' ALKS 7290 Shows Promising ADHD Results in Phase 1b Trial
Event summary
- Alkermes' ALKS 7290 demonstrated clinically meaningful improvements in ADHD symptoms in a Phase 1b trial with 50 adults.
- The study showed dose-dependent reductions in AISRS scores (14.0 points for 20 mg, 19.0 points for 50 mg) and CGI-S scores (1.0 and 2.0 points respectively) at day 14.
- ALKS 7290 was generally well-tolerated with no serious adverse events reported.
- A Phase 2 study for ALKS 7290 in ADHD is currently enrolling 312 participants, with first dosing in September 2026.
The big picture
Alkermes' positive Phase 1b results for ALKS 7290 mark a significant step in exploring the orexin pathway for ADHD treatment, a condition affecting millions of adults. The company's strategy to expand its orexin portfolio beyond hypersomnolence disorders aligns with broader industry trends toward novel mechanisms for neurological conditions. The success of ALKS 7290 could potentially open new therapeutic avenues in ADHD, a market dominated by stimulant-based treatments.
What we're watching
- Clinical Validation
- Whether ALKS 7290 can sustain its promising Phase 1b results in the ongoing Phase 2 trial.
- Regulatory Pathway
- The pace at which Alkermes can advance ALKS 7290 through subsequent clinical stages and potential regulatory approval.
- Market Differentiation
- How ALKS 7290's orexin 2 receptor agonist mechanism will position it against existing ADHD treatments.